EPIGENOMICS AG NPV (POST CONVERSION)EPIGENOMICS AG NPV (POST CONVERSION)EPIGENOMICS AG NPV (POST CONVERSION)

EPIGENOMICS AG NPV (POST CONVERSION)

No trades
See on Supercharts

0QXH fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G. Gut in 1998 and is headquartered in Berlin, Germany.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0QXH does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company